Arcus Biosciences stock gains 1.49 percent ahead of data event

Published on 10/05/2026 at 18:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Arcus Biosciences stock was trading at USD 24.80 on October 5, 2026, as investors awaited new casdatifan data. Q2 revenue reached USD 41.0 million.

RCUS, US03969F1093, Illustration mit AI erstellt.

Arcus Biosciences stock (ISIN US03969F1093) was trading at USD 24.80 on the NYSE at 12:48 p.m. ET on October 5, 2026, up 1.49 percent during the session. The immediate company catalyst is an October 20 investor event featuring new casdatifan data across several kidney cancer treatment settings. The setup combines a near-term clinical readout with a valuation gap to the analyst consensus.

Casdatifan data set for October 20

According to Yahoo Finance on September 22, 2026, Arcus will present new data from the ARC-20 platform study at an investor event on October 20, 2026. The program covers casdatifan alone and in combinations for first-line, second-line and late-line clear cell renal cell carcinoma.

The planned presentation includes data from 30 patients in a first-line casdatifan and zimberelimab cohort, 43 patients in a casdatifan and cabozantinib cohort, and 121 patients in pooled late-line monotherapy cohorts. Arcus also plans to show early overall-survival information and translational data linking HIF-2 inhibition markers with overall survival, making the event more consequential than a routine corporate presentation.

Revenue beat meets a deeper loss

Arcus reported USD 41.0 million of revenue in Q2 2026, versus a USD 21.98 million consensus estimate, while diluted EPS was negative USD 0.72 against a negative USD 0.89 estimate, according to MarketBeat on September 16, 2026. The revenue result exceeded consensus by USD 19.02 million, but revenue was down 74.4 percent year over year, underscoring the volatility of a clinical-stage biotechnology business.

The Q2 net loss was USD 91.0 million, compared with USD 128.0 million in Q1 2026. Arcus describes itself as a clinical-stage biopharmaceutical company developing cancer medicines, so the October data event matters because clinical progress, rather than recurring product sales, remains the central operating driver, according to Arcus Biosciences.

Consensus target stays above the quote

MarketBeat reported a Moderate Buy consensus from 13 analysts on September 16, 2026, with nine Buy ratings, three Holds and one Sell. The average 12-month target was USD 38.30, which places the target 54.4 percent above the USD 24.80 intraday price.

The range of views is material: Wells Fargo had an Equal Weight rating with a USD 26.00 target, while Wedbush maintained an Outperform rating and a USD 43.00 target, both cited by MarketBeat. For investors, the October data will test whether the pipeline can justify that wide target spread.

Arcus Biosciences stock gains in trading

Arcus Biosciences stock was last at USD 24.80 on the NYSE on October 5, 2026, with 448,984 shares traded. Its 52-week range was USD 13.61 to USD 31.74, while market capitalization stood at USD 3.1 billion on the same date.